Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
664 studies found for:    ovarian cancer | Open Studies
Show Display Options
Rank Status Study
21 Recruiting Impact of Gated PET/CT in the Diagnosis of Advanced Ovarian Cancer
Conditions: Ovarian Cancer Stage III;   Ovarian Cancer Stage IV
Intervention: Device: PET/CT
22 Not yet recruiting Improving Quality of Care for Patients With Recurrent Ovarian Cancer
Conditions: Ovarian Neoplasms;   Quality of Life
Intervention: Other: Questionnaires
23 Recruiting Safety and Efficacy Study of Nuc-1031 and Carboplatin Combination to Treat Recurrent Ovarian Cancer
Condition: Recurrent Ovarian Cancer
Intervention: Drug: Nuc-1031 and Carboplatin
24 Recruiting BELOVA Data Collection: Safety and Efficacy of Frontline Bevacizumab Treatment in Participants With Ovarian Cancer 70 Years and Older
Condition: Ovarian Cancer
Interventions: Drug: Bevacizumab;   Drug: Carboplatin;   Drug: Paclitaxel
25 Not yet recruiting Treatment for Malignant Ovarian Cancer: Laparoscopy vs Laparotomy
Condition: Ovarian Cancer
Interventions: Procedure: Laparoscopy;   Procedure: Laparotomy
26 Recruiting Prognostic and Predictive Value of HE4 Biomarker in Metastatic Ovarian Cancer
Condition: Metastatic Ovarian Cancer
Intervention: Other: Experimental arm
27 Recruiting Observational Retrospective Study on Treatment and Outcomes in Patients With Low-grade Serous Ovarian Cancer
Conditions: Low-grade Serous Ovarian Carcinoma;   Recurrent Invasive Borderline Serous Ovarian Cancer
Intervention:
28 Recruiting Data Collection for Patients With Low Grade Ovarian Carcinoma
Conditions: Ovarian Cancer;   Peritoneum Tumors
Intervention: Behavioral: Data Collection
29 Not yet recruiting HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma
Conditions: Epithelial Ovarian Cancer;   Renal Cell Carcinoma
Intervention: Drug: HKT288
30 Recruiting Cabazitaxel vs. Tocotrienol in Patients With Recurrent Ovarian Cancer After Failure of Standard Therapy.
Condition: Ovarian Cancer
Interventions: Drug: Cabazitaxel;   Drug: Tocotrienol
31 Recruiting Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: Apatinib;   Drug: Etoposide
32 Recruiting A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer
Conditions: Ovarian Cancer;   Breast Cancer;   Prostate Cancer
Intervention: Drug: LY2606368
33 Recruiting EWOC-1 Trial: Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: Paclitaxel + Carboplatin every 3 weeks;   Drug: Carboplatin monotherapy every 3 weeks;   Drug: Weekly Paclitaxel and Carboplatin
34 Recruiting EC17 for Intraoperative Imaging in Occult Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Drug: EC17
35 Recruiting Mesenchymal Stem Cells (MSC) for Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Genetic: MSC-INFβ;   Behavioral: Questionnaires
36 Recruiting Sexual Therapy and Rehabilitation After Treatment for Ovarian Cancer (START-OC): A Pilot Intervention
Condition: Ovarian Cancer
Interventions: Behavioral: Group Session;   Behavioral: Telephone Coaching Session;   Behavioral: Webinar
37 Recruiting Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer
Condition: Recurrent Ovarian Cancer
Intervention: Drug: LDE225
38 Recruiting Study of Metformin With Carboplatin/Paclitaxel Chemotherapy in Patients With Advanced Ovarian Cancer
Condition: Epithelial Ovarian Cancer
Interventions: Drug: Metformin;   Drug: Carboplatin;   Drug: Paclitaxel
39 Recruiting Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer
Condition: Ovarian Cancer
Interventions: Drug: Pembrolizumab;   Drug: Carboplatin;   Drug: Paclitaxel
40 Recruiting CT Antigen TCR-redirected T Cells for Ovarian Cancer.
Condition: Ovarian Cancer
Intervention: Biological: NYESO-1c259 T cells

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.